Interventional Cardiology
STEMI management
ST-elevation MI treatment and primary PCI
Emerging pathwayAlso known as: ST elevation MI, primary PCI, STEMI protocol
818
Clinical questions
335
Evidence-backed
100
Claims analyzed
Interventional Cardiology
ST-elevation MI treatment and primary PCI
Synthesized from 335 evidence-backed clinical questions linked to this topic — 16 supporting the intervention, 25 against the intervention, 6 still contested.
Does ticagrelor vs clopidogrel improve outcomes in Acute Coronary Syndrome?
Low Certainty− Favors harmticagrelor vs clopidogrel · Cardiac Output
62 studies (729,408 patients) provide low-certainty evidence against benefit of ticagrelor for Cardiac Output in Acute Coronary Syndrome.
Does aspirin vs placebo improve outcomes in ST segment elevation myocardial infarction?
Low Certainty− Favors harmaspirin vs placebo
10 studies (212,459 patients) provide low-certainty evidence against benefit of aspirin for the outcome in ST segment elevation myocardial infarction.
Does ticagrelor vs clopidogrel improve outcomes in ST segment elevation myocardial infarction?
Low Certainty+ Favors benefitticagrelor vs clopidogrel · Myocardial Infarction Hospitalization
17 studies (206,473 patients) provide low-certainty evidence for benefit of ticagrelor for Myocardial Infarction Hospitalization in ST segment elevation myocardial infarction.
Does women vs placebo improve outcomes in ST segment elevation myocardial infarction?
Low Certainty− Favors harmwomen vs placebo
3 studies (180,455 patients) provide low-certainty evidence against benefit of women for the outcome in ST segment elevation myocardial infarction.
Does prasugrel vs ticagrelor improve outcomes in ST segment elevation myocardial infarction?
Low Certainty+ Favors benefitprasugrel vs ticagrelor
3 studies (170,048 patients) provide low-certainty evidence for benefit of prasugrel for the outcome in ST segment elevation myocardial infarction.
Does beta-blockers vs placebo improve outcomes in ST segment elevation myocardial infarction?
Low Certainty+ Favors benefitbeta-blockers vs placebo
10 studies (165,196 patients) provide low-certainty evidence for benefit of beta-blockers for the outcome in ST segment elevation myocardial infarction.
Does anakinra vs placebo improve outcomes in ST segment elevation myocardial infarction?
Insufficient~ Mixed resultsanakinra vs placebo · Myocardial Infarction Hospitalization
6 studies (586 patients) provide insufficient evidence with mixed findings regarding anakinra for Myocardial Infarction Hospitalization in ST segment elevation myocardial infarction.
Does eptifibatide vs placebo improve outcomes in ST segment elevation myocardial infarction?
Insufficient~ Mixed resultseptifibatide vs placebo
6 studies (997 patients) provide insufficient evidence with mixed findings regarding eptifibatide for the outcome in ST segment elevation myocardial infarction.
Emerging evidence with 100 primary claims
Specific, answerable questions in this area — each with its own synthesized evidence and consensus. Open one to see the forest plot, source trials, and how the consensus has changed over time.
Does fibrinolytic therapy vs placebo improve outcomes in ST segment elevation myocardial infarction?
Low Certainty+ Favors benefitfibrinolytic therapy vs placebo · Myocardial Infarction Hospitalization
Does ticagrelor vs clopidogrel improve Myocardial Infarction Hospitalization in ST segment elevation myocardial infarction?
Low Certainty+ Favors benefitticagrelor vs clopidogrel · Myocardial Infarction Hospitalization
Sessions from public journal clubs on Synapse. RSVP to join the live discussion.
ST‐elevation myocardial infarction in a migrant population: a registry‐based study of patient treatment and outcomes
Internal Medicine Journal — Rye E — Aug 2018
Epidemiology and risk factors of patients with types of acute coronary syndrome presenting to a tertiary care hospital in Sri Lanka
BMC Cardiovascular Disorders — Ralapanawa U — Oct 2019
CVIT expert consensus document on primary percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI) update 2022
Cardiovascular Intervention and Therapeutics — Jan 2022
Comprehensive prediction of outcomes in patients with ST elevation myocardial infarction (STEMI) using tree-based machine learning algorithms
Computers in Biology and Medicine — Razavi S — Nov 2024
Human Bone Marrow Mesenchymal Stem Cells Promote the M2 Phenotype in Macrophages Derived from STEMI Patients
Follow this topic to get a weekly “what changed” evidence digest and alerts when journal clubs schedule sessions on it.
STEMI management (also known as ST elevation MI, primary PCI, STEMI protocol). ST-elevation MI treatment and primary PCI
Synapse tracks 6 specific clinical questions in STEMI management, each synthesized independently from its own trial evidence. They include: "Does fibrinolytic therapy vs placebo improve outcomes in ST segment elevation myocardial infarction?"; "Does ticagrelor vs clopidogrel improve Myocardial Infarction Hospitalization in ST segment elevation myocardial infarction?"; "Does metoprolol vs placebo improve Myocardial Infarction Hospitalization in ST segment elevation myocardial infarction?"; "Does metoprolol vs placebo improve outcomes in ST segment elevation myocardial infarction?"; "Does anakinra vs placebo improve Myocardial Infarction Hospitalization in ST segment elevation myocardial infarction?".
As of 2026-08-14, the scientific consensus on STEMI management is emerging. Emerging evidence with 100 primary claims Based on 100 analyzed claims across Synapse's enriched corpus, the evidence shows.
This evidence brief synthesizes Synapse's enriched cardiology corpus; cite as synapsesocial.com/topics/stemi-management.
Deterministic synthesis from Synapse's enriched corpus — 144 words. No AI-generated novel content; every figure is sourced from the underlying paper, guideline, or trial record linked on this page.
Explore every STEMI management paper on Synapse with AI-enriched clinical evidence, PICO analysis, and methodology classification.
Search STEMI management papersPowered by Synapse — AI-enriched analysis of 600,000+ peer-reviewed papers
International Journal of Molecular Sciences — Cortés-Morales V — Nov 2023